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Baseline Cardiovascular Characteristics of Adult Patients with 
Chronic Kidney Disease from the KoreaN Cohort Study for 
Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD)
Cardiovascular disease (CVD) is the most common cause of death in patients with chronic 
kidney disease (CKD). We report the baseline cardiovascular characteristics of 2,238 
participants by using the data of the KoreaN Cohort Study for Outcomes in Patients With 
Chronic Kidney Disease (KNOW-CKD) study. The cohort comprises 5 subcohorts according 
to the cause of CKD: glomerulonephritis (GN), diabetic nephropathy (DN), hypertensive 
nephropathy (HTN), polycystic kidney disease (PKD), and unclassified. The average 
estimated glomerular filtration rate (eGFR) was 50.5 ± 30.3 mL/min−1/1.73 m−2 and lowest 
in the DN subcohort. The overall prevalence of previous CVD was 14.4% in all patients, 
and was highest in the DN followed by that in the HTN subcohort. The DN subcohort had 
more adverse cardiovascular risk profiles (higher systolic blood pressure [SBP], and higher 
levels of cardiac troponin T, left ventricular mass index [LVMI], coronary calcium score, and 
brachial-ankle pulse wave velocity [baPWV]) than the other subcohorts. The HTN subcohort 
exhibited less severe cardiovascular risk profiles than the DN subcohort, but had more 
severe cardiovascular risk features than the GN and PKD subcohorts. All these 
cardiovascular risk profiles were inversely correlated with eGFR. In conclusion, this study 
shows that the KNOW-CKD cohort exhibits high cardiovascular burden, as other CKD 
cohorts in previous studies. Among the subcohorts, the DN subcohort had the highest risk 
for CVD. The ongoing long-term follow-up study up to 10 years will further delineate 
cardiovascular characteristics and outcomes of each subcohort exposed to different risk 
profiles.
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INTRODUCTION
The number of patients with end-stage renal disease (ESRD) 
requiring renal replacement therapy has been consistently in-
creasing during the last decades and has become a socio-eco-
nomic burden worldwide, including in Korea. A recent survey 
from the ESRD registry database of the Korean Society of Ne-
phrology showed that the annual growth rate of dialysis-depen-
dent ESRD patients was 9% during 2000–2013 (1). The preva-
lence of predialysis chronic kidney disease (CKD) has been re-
ported to be 10%–14% in North America and Japan (2-5) and 
8.2%–13.8% in Korea (6,7).
 Cardiovascular disease (CVD) is the most common cause of 
death in ESRD patients, and even in predialysis patients with 
CKD, the risk of CVD increases as the estimated glomerular fil-
tration rate (eGFR) decreases, particularly at a level < 60 mL/
min−1/1.73 m−2 (8). Of note, many CKD patients die of CVD be-
fore they progress to ESRD (9). It is well known that CVD is high-
ly prevalent in patients with CKD. The Chronic Renal Insuffi-
ciency Cohort study reported that 34.0% of CKD patients in the 
United States had ischemic heart disease or heart failure (10). 
Interestingly, cardiovascular prevalence and mortality can vary 
among different ethnic groups, and racial differences and so-
cioeconomic disparities can determine the clinical outcomes of 
CKD patients (11-14). However, studies examining cardiovas-
cular characteristics in Asian patients with CKD are scarce. In a 
Japanese cohort study, the prevalence of CVD was 25.6% (15); 
however, only patients with an eGFR of 10–59 mL/min−1/1.73 
m−2 were included, and thus patients with early stages of CKD 
were excluded. Recently, the Kidney Disease: Improving Global 
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Outcomes (KDIGO) guidelines adopted the importance of al-
buminuria and proposed a new CKD staging based on cause, 
glomerular filtration rate category, and albuminuria category 
(the CGA staging system) (16). In fact, albuminuria is an impor-
tant risk factor of CVD in the general population (17), and the 
risk of cardiovascular mortality significantly increases in patients 
with a urine albumin-creatinine ratio of > 30 mg/g with a pre-
served eGFR of ≥ 60 mL/min/1.73 m2 (18).
 With this background, the KoreaN Cohort Study for Outcome 
in Patients With Chronic Kidney Disease (KNOW-CKD) was 
initiated in 2011. The cohort comprises 5 subcohorts and en-
compasses early stages of CKD. The main purposes of the KNOW-
CKD study are to define the clinical characteristics of Korean 
CKD patients, and to identify factors associated with kidney dis-
ease progression and mortality. This study particularly details 
the baseline cardiovascular characteristics of those patients.
MATERIALS AND METHODS
Study protocol and population
The KNOW-CKD study is a nationwide prospective cohort study 
involving 9 tertiary-care general hospitals: Seoul National Uni-
versity Hospital, Seoul National University Bundang Hospital, 
Yonsei University Severance Hospital, Kangbuk Samsung Med-
ical Center, Seoul St. Mary’s Hospital, Gil Hospital, Eulji General 
Hospital, Chonnam National University Hospital, and Pusan 
Paik Hospital. The rationale, design, inclusion criteria, and meth-
od of the study were described in detail elsewhere (19) (NCT-
01630486 at http://www.clinicaltrials.gov). Between 2011 and 
2015, information of the study had been provided for the pati-
ents who were treated in each center. Informed consent encom-
passed study’s purpose, duration, procedures, alternatives, risks, 
benefits, and subject’s rights to withdraw of the study at any time. 
As a result, 2,341 participants who voluntarily provided informed 
consent were enrolled. We additionally excluded 103 partici-
pants who violated the inclusion criteria, or had no data of iso-
tope dilution mass spectrometry (IDMS)-calibrated creatinine. 
Therefore, a total of 2,238 participants were finally included in 
the study. The CKD stages were classified according to eGFR 
calculated by using the Modification of Diet in Renal Disease 
equation (20).
 All subjects were categorized into 5 subcohorts according to 
the etiology of CKD: glomerulonephritis (GN), diabetic nephrop-
athy (DN), hypertensive nephropathy (HTN), and polycystic 
kidney disease (PKD). The patients with CKD of unknown ori-
gin was classified into ‘Unclassified’ group. The definition and 
diagnosis were defined on the basis of pathologic results in sub-
jects who underwent kidney biopsy. Otherwise, clinical diagno-
sis was made with caution by nephrologists based on demogra-
phic, clinical, and laboratory data. The details of the definition 
of each disease category were described elsewhere (19). 
Data collection
Baseline socio-demographic characteristics; clinical informa-
tion such as comorbid diseases, family history, smoking status, 
and medication history; and anthropometric data such as height, 
weight, and waist-to-hip ratio were collected at enrollment. In 
addition, blood pressure was measured by using an electronic 
sphygmomanometer after 5 minutes of seated rest. The pres-
ence of CVD was defined as a history of myocardial infarction 
(MI), coronary revascularization, coronary artery bypass graft, 
peripheral arterial disease, ischemic or hemorrhagic cerebro-
vascular disease, or arrhythmia. To assess cardiovascular risk, 
the coronary arterial calcification (CAC) score, left ventricular 
mass index (LVMI), and pulse wave velocity (PWV) were mea-
sured at each center. CAC and LVMI were determined by using 
multidetector computed tomography (CT) and 2-dimensional 
echocardiography, respectively. LVMI was calculated from the 
left ventricular mass divided by the body surface area. Left ven-
tricular geometry was categorized into 4 groups according to 
relative wall thickness and LVMI: normal, concentric remodel-
ing, eccentric left ventricular hypertrophy (LVH), and concen-
tric LVH (21). PWV was defined as the calculated distance be-
tween the arm and leg from the height divided by the time de-
lay between proximal and distal foot waveforms obtained from 
plethysmographic and oscillometric sensors (brachial-ankle 
PWV [baPWV]). Blood samples were obtained at each center, 
and 10 mL of whole blood in a serum separation tube was cen-
trifuged within 1 hour for serum separation and sent to a cen-
tral laboratory. First-voided urine samples (15 mL) were col-
lected to measure urine albumin, protein, and creatinine. Pa-
tients were classified into 3 groups according to urine albumin 
to creatinine ratio (ACR): ACR < 30 mg/g for A1, 30 ≤ ACR < 300 
mg/g for A2, ACR ≥ 300 mg/g for A3.
Statistical analysis
Continuous variables are expressed as mean ± standard devia-
tion, and compared with 1-way analysis of variance. To compare 
variables between 2 groups, post-hoc analysis was performed 
with Bonferroni analysis. The normality of the distribution of 
parameters was analyzed by using the Kolmogorov-Smirnov 
test. Nonparametric variables are expressed as median and rang-
es (mininum to maximum), and compared by using the Krus-
kal-Wallis test. Categorical variables are expressed as numbers 
and percentages, and compared by using χ2 test. Univariate cor-
relation analysis was performed with Spearman correlation anal-
ysis to assess the relationship between eGFR and other param-
eters. Statistical significance was defined as P < 0.05, and all anal-
yses were conducted with SPSS version 20.0 (IBM Corporation, 
Armonk, NY, USA).
Ethics statement
The study was carried out in accordance with the principles of 
Kim H, et al. • Cardiovascular Characteristics in the KNOW-CKD Cohort
http://jkms.org  233https://doi.org/10.3346/jkms.2017.32.2.231
the Declaration of Helsinki. The present study protocol was re-
viewed and approved by the Institutional Review Boards at each 
participating center (IRB approval number of Yonsei University 
Severance Hospital: 4-2011-0163). Written informed consent was 
obtained from all participants before enrollment. The protocol 
summary was also registered at ClinicalTrials.gov (NCT01630486).
RESULTS
Baseline characteristics
The baseline characteristics of the patients according to subco-
horts are presented in Table 1. We compared 4 subcohorts whose 
etiology of CKD had been confirmed, and present baseline char-
Table 1. Baseline characteristics and prevalence of CVD according to the etiology of CKD
Characteristics
Subcohort
Total P value
DN HTN GN PKD
Participants 519 409 810 364 2,238
Age, yr 59.3 ± 9.4 59.6 ± 10.8 49.8 ± 12.1 46.9 ± 10.6 53.7 ± 12.2 < 0.001
Female 162 (31.2) 114 (27.9) 359 (44.3) 180 (49.5) 869 (38.8) < 0.001
Hypertension 513 (99.8) 409 (100.0) 785 (96.9) 314 (86.3) 2,150 (96.1) < 0.001
DM 519 (100.0) 72 (17.6) 70 (8.6) 12 (3.3) 755 (33.7) < 0.001
Current smoker 84 (16.4) 71 (17.4) 115 (14.2) 55 (15.1) 349 (15.7) < 0.001
Height, cm 164.5 ± 8.2 164.8 ± 8.2 164.3 ± 8.2 166.1 ± 9.1 164.7 ± 8.4 0.040
Weight, kg 68.4 ± 11.4 68.4 ± 12.3 65.6 ± 11.7 65.2 ± 12.0 66.8 ± 11.9 < 0.001
BMI, kg/m2 25.2 ± 3.2 25.1 ± 3.5 24.2 ± 3.3 23.5 ± 3.0 24.6 ± 3.4 < 0.001
Waist-to-hip ratio 0.93 ± 0.06 0.91 ± 0.06 0.88 ± 0.07 0.88 ± 0.06 0.90 ± 0.07 < 0.001
SBP, mmHg 134.3 ± 18.5 127.8 ± 15.9 123.4 ± 14.2 128.3 ± 13.3 127.8 ± 16.2 < 0.001
DBP, mmHg 75.7 ± 11.7 77.7 ± 11.5 75.6 ± 10.1 81.0 ± 10.4 77.0 ± 11.1 < 0.001
CKD stages < 0.001
   Stage 1 13 (2.5) 11 (2.7) 131 (16.2) 94 (25.8) 265 (11.8)
   Stage 2 44 (8.5) 48 (11.7) 180 (22.2) 118 (32.4) 419 (18.7)
   Stage 3a 72 (13.9) 95 (23.2) 163 (20.1) 52 (14.3) 403 (18.0)
   Stage 3b 131 (25.2) 112 (27.4) 158 (19.5) 45 (12.4) 484 (21.6)
   Stage 4 198 (38.2) 118 (28.9) 138 (17.0) 42 (11.5) 522 (23.3)
   Stage 5 61 (11.8) 25 (6.1) 40 (4.9) 13 (3.6) 145 (6.5)
CVD
   Any CVD 130 (25.0) 88 (21.5) 56 (6.9) 25 (6.9) 322 (14.4) < 0.001
   Coronary disease 60 (11.6) 32 (7.8) 14 (1.7) 2 (0.5) 118 (5.3) < 0.001
   MI 18 (3.5) 9 (2.2) 6 (0.7) 1 (0.3) 36 (1.6) < 0.001
   Stroke 51 (9.8) 38 (9.3) 19 (2.3) 21 (5.8) 135 (6.0) < 0.001
   PAD 32 (6.2) 20 (4.9) 13 (1.6) 1 (0.3) 78 (3.5) < 0.001
   Arrhythmia 16 (3.1) 18 (4.4) 18 (2.2) 2 (0.5) 56 (2.5) 0.006
Urine ACR, mg/g < 0.001
   A1 ( < 30) 21 (4.3) 101 (26.1) 44 (5.8) 151 (42.9) 336 (15.9)
   A2 (30–300) 101 (20.5) 126 (32.6) 214 (28.4) 169 (48.0) 641 (30.4)
   A3 ( ≥ 300) 370 (75.2) 160 (41.3) 496 (65.8) 32 (9.1) 1,134 (53.7)
Creatinine, mg/dL 2.4 ± 1.3 2.0 ± 1.2 1.6 ± 1.0 1.3 ± 0.9 1.8 ± 1.1 < 0.001
Cystatin C, mg/L 2.3 ± 1.0 1.9 ± 0.9 1.6 ± 0.9 1.3 ± 0.7 1.8 ± 0.9 < 0.001
eGFR, mL/min/1.73 m2 35.2 ± 20.6 40.8 ± 21.2 56.9 ± 31.8 68.1 ± 33.3 50.5 ± 30.3 < 0.001
Total cholesterol, mg/dL 178.9 ± 33.5 167.3 ± 43.7 169.3 ± 35.6 178.4 ± 39.0 178.9 ± 33.5 < 0.001
LDL cholesterol, mg/dL 91.0 ± 33.9 94.1 ± 30.8 100.1 ± 32.4 101.8 ± 27.1 96.9 ± 31.8 < 0.001
HDL cholesterol, mg/dL 43.6 ± 14.1 46.7 ± 14.1 51.5 ± 15.8 54.6 ± 14.0 49.2 ± 15.4 < 0.001
Hemoglobin, g/dL 11.7 ± 1.8 13.3 ± 2.0 13.2 ± 1.9 13.2 ± 1.8 12.8 ± 2.0 < 0.001
Albumin, g/dL 4.0 ± 0.5 4.3 ± 0.3 4.1 ± 0.4 4.4 ± 0.3 4.2 ± 0.4 < 0.001
Phosphorus, mg/dL 4.0 ± 0.8 3.6 ± 0.6 3.6 ± 0.6 3.6 ± 0.6 3.7 ± 0.7 < 0.001
Troponin T, ng/mL 0.029 ± 0.031 0.015 ± 0.015 0.01 ± 0.009 0.007 ± 0.004 0.015 ± 0.019 < 0.001
hsCRP, mg/L* 0.7 (0.1–52.7) 0.8 (0.0–67.0) 0.5 (0.0–68.0) 0.4 (0.0–35.3) 0.6 (0.0–68.0) < 0.001
Intact PTH, pg/mL* 63.4 (14.2–1,078.0) 52.3 (19.1–660.3) 44.4 (7.0–552.3) 56.3 (21.8–414.9) 51.0 (7.0–1,078.0) < 0.001
ARB 419 (80.7) 318 (77.8) 669 (82.6) 270 (74.2) 1,785 (79.8) 0.025
ACEi 63 (12.1) 33 (8.1) 123 (15.2) 18 (4.9) 249 (11.1) < 0.001
CCB 295 (56.8) 218 (53.3) 216 (26.7) 120 (33.0) 906 (40.5) < 0.001
Statin 329 (63.4) 234 (57.2) 419 (51.7) 98 (26.9) 1,152 (51.5) < 0.001
Values are presented as number (%) or mean ± standard deviation.
CVD = cardiovascular disease, CKD = chronic kidney disease, DN = diabetic nephropathy, HTN = hypertensive nephropathy, GN = glomerulonephritis, PKD = polycystic kidney 
disease, BMI = body mass index, DM = diabetes mellitus, SBP = systolic blood pressure, DBP = diastolic blood pressure, MI = myocardial infarction, PAD = peripheral arterial 
disease, ACR = albumin-to-creatinine ratio, eGFR = estimated glomerular filtration rate, LDL = low-density lipoprotein, HDL = high-density lipoprotein hsCRP = high-sensitive 
C-reactive protein, PTH = parathyroid hormone, ARB = angiotensin receptor blocker, ACEi = angiotensin converting enzyme inhibitor, CCB = calcium channel blocker.
*Data are expressed as median and ranges (minimum to maximum).
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acteristics of unclassified subcohort in Supplementary Table 1. 
The mean age was 53.7 ± 12.2 years, and patients in the DN and 
HTN subcohorts were older than those in the other 2 subcohorts 
(P < 0.001). Almost all patients (96.1%) had hypertension, and 
the mean systolic blood pressure (SBP) and diastolic blood pres-
sure (DBP) were 127.8 ± 16.2 and 77.0 ± 11.1 mmHg, respec-
tively. The mean level of random urine albumin-to-creatinine 
ratio was 901.4 mg/g. The mean creatinine level and eGFR of 
the entire cohort were 1.8 ± 1.1 mg/dL and 50.5 ± 30.3 mL/min−1/ 
1.73 m−2, respectively. The HTN subcohort had more male pa-
tients and current smokers than the other subcohorts. The DN 
subcohort had higher body mass index (BMI) and lower levels 
Table 2. Baseline characteristics and prevalence of CVD according to CKD stages
Characteristics
CKD stage P for  
trendStage 1 Stage 2 Stage 3a Stage 3b Stage 4 Stage 5
Participants 265 419 403 484 522 145
Age, yr 43.2 ± 11.7 50.5 ± 11.7 54.9 ± 11.7 56.7 ± 11.0 57.2 ± 11.1 55.7 ± 11.4 < 0.001
Female 138 (52.1) 142 (33.9) 127 (31.5) 177 (36.6) 208 (39.8) 77 (53.1) 0.720
Hypertension 225 (84.9) 399 (95.2) 395 (98.0) 475 (98.1) 515 (98.7) 143 (98.6) < 0.001
DM 40 (15.1) 87 (20.8) 119 (29.5) 192 (39.7) 249 (47.7) 68 (46.9) < 0.001
Current smoker 42 (15.8) 69 (16.5) 78 (19.4) 66 (13.6) 76 (14.6) 18 (12.4) 0.120
Height, cm 165.2 ± 8.2 166.6 ± 8.6 165.5 ± 8.2 164.0 ± 8.0 163.6 ± 8.3 161.5 ± 8.5 < 0.001
Weight, kg 66.3 ± 13.4 68.7 ± 12.5 68.0 ± 12.0 66.7 ± 10.4 65.7 ± 11.6 63.5 ± 11.5 < 0.001
BMI, kg/m2 24.2 ± 3.8 24.6 ± 3.4 24.7 ± 3.3 24.8 ± 3.2 24.4 ± 3.4 24.2 ± 3.4 0.840
Waist-to-hip ratio 0.88 ± 0.07 0.89 ± 0.07 0.90 ± 0.06 0.91 ± 0.08 0.91 ± 0.06 0.90 ± 0.06 < 0.001
SBP, mmHg 126.6 ± 14.3 126.4 ± 14.7 126.5 ± 15.7 126.8 ± 15.5 129.7 ± 17.6 135.1 ± 20.0 < 0.001
DBP, mmHg 78.6 ± 10.5 78.3 ± 11.3 76.6 ± 10.3 76.0 ± 10.5 76.4 ± 12.1 77.4 ± 11.8 0.003
Primary kidney disease < 0.001
   GN 131 (49.4) 180 (43.0) 163 (40.4) 158 (32.6) 138 (26.4) 40 (27.6)
   DN 13 (4.9) 44 (10.5) 72 (17.9) 131 (27.1) 198 (37.9) 61 (42.1)
   HTN 11 (4.2) 48 (11.5) 95 (23.6) 112 (23.1) 118 (22.6) 25 (17.2)
   PKD 94 (35.5) 118 (28.2) 52 (12.9) 45 (9.3) 42 (8.0) 13 (9.0)
   Unclassified 16 (6.0) 29 (6.9) 21 (5.2) 38 (7.9) 26 (5.0) 6 (4.1)
CVD
   Any CVD 15 (5.7) 38 (9.1) 59 (14.6) 76 (15.7) 110 (21.1) 24 (16.6) < 0.001
   Coronary disease 2 (0.8) 10 (2.4) 17 (4.2) 33 (6.8) 48 (9.2) 8 (5.5) < 0.001
   MI 0 (0.0) 3 (0.7) 5 (1.2) 12 (2.5) 14 (2.7) 2 (1.4) 0.002
   Stroke 6 (2.3) 15 (3.6) 28 (6.9) 32 (6.6) 45 (8.6) 9 (6.2) < 0.001
   PAD 3 (1.1) 7 (1.7) 18 (4.5) 16 (3.3) 29 (5.6) 5 (3.4) 0.002
   Arrhythmia 5 (1.9) 9 (2.1) 11 (2.7) 9 (1.9) 19 (3.6) 3 (2.1) 0.280
Urine ACR, mg/g < 0.001
   A1 ( < 30) 79 (31.1) 114 (29.2) 65 (17.2) 51 (11.1) 23 (4.7) 4 (2.9)
   A2 (30–300) 80 (31.5) 124 (31.7) 130 (34.3) 154 (33.6) 129 (26.3) 24 (17.3)
   A3 ( ≥ 300) 95 (37.4) 153 (39.1) 184 (48.5) 253 (55.2) 338 (69.0) 111 (79.9)
Creatinine, mg/dL 0.7 ± 0.1 1.0 ± 0.2 1.3 ± 0.2 1.7 ± 0.3 2.7 ± 0.6 4.8 ± 1.6 < 0.001
Cystatin C, mg/L 0.8 ± 0.1 1.0 ± 0.2 1.3 ± 0.2 1.8 ± 0.3 2.6 ± 0.5 3.9 ± 0.7 < 0.001
eGFR, mL/min/1.73 m2 110.9 ± 20.6 73.3 ± 8.6 52.2 ± 4.3 37.3 ± 4.2 23.1 ± 4.4 11.8 ± 2.4 < 0.001
Total cholesterol, mg/dL 185.3 ± 38.1 179.5 ± 35.7 173.3 ± 35.9 170.6 ± 39.3 169.6 ± 42.3 168.9 ± 42.8 < 0.001
LDL cholesterol, mg/dL 107.3 ± 33.1 102.3 ± 30.5 96.5 ± 30.4 92.4 ± 30.2 92.7 ± 32.4 93.7 ± 34.4 < 0.001
HDL cholesterol, mg/dL 56.9 ± 15.6 52.6 ± 15.6 49.6 ± 14.1 47.2 ± 14.3 45.3 ± 14.7 45.3 ± 16.6 < 0.001
Hemoglobin, g/dL 14.0 ± 1.5 14.1 ± 1.7 13.5 ± 1.9 12.7 ± 1.8 11.5 ± 1.5 10.5 ± 1.2 < 0.001
Albumin, g/dL 4.3 ± 0.4 4.3 ± 0.4 4.2 ± 0.4 4.2 ± 0.4 4.0 ± 0.5 3.9 ± 0.4 < 0.001
Phosphorus, mg/dL 3.5 ± 0.5 3.5 ± 0.6 3.5 ± 0.5 3.6 ± 0.6 3.9 ± 0.7 4.7 ± 0.8 < 0.001
Troponin T, ng/mL 0.006 ± 0.003 0.008 ± 0.006 0.011 ± 0.007 0.015 ± 0.014 0.025 ± 0.027 0.032 ± 0.033 < 0.001
hsCRP, mg/L* 0.4 (0.0–68.0) 0.6 (0.0–32.0) 0.6 (0.0–60.2) 0.6 (0.0–54.5) 0.8 (0.1–67.0) 0.7 (0.1–26.1) 0.001
Intact PTH, pg/mL* 37.3 (9.7–95.6) 38.4 (7.0–140.3) 44.6 (8.4–225.0) 53.5 (14.0–184.7) 87.8 (14.1–590.9) 175.1 (37.6–1,078.0) < 0.001
ARB 186 (70.2) 344 (82.1) 330 (81.9) 398 (82.2) 411 (78.7) 116 (80.0) 0.120
ACEi 33 (12.5) 51 (12.2) 53 (13.2) 49 (10.1) 49 (9.4) 14 (9.7) 0.060
CCB 56 (21.1) 133 (31.7) 150 (37.2) 212 (43.8) 268 (51.3) 87 (60.0) < 0.001
Statin 92 (34.7) 193 (46.1) 224 (55.6) 285 (58.9) 277 (53.1) 81 (55.9) < 0.001
Data are expressed as number (%) or mean ± standard deviation.
CVD = cardiovascular disease, CKD = chronic kidney disease, BMI = body mass index, DM = diabetes mellitus, SBP = systolic blood pressure, DBP = diastolic blood pressure, 
GN = glomerulonephritis, DN = diabetic nephropathy, HTN = hypertensive nephropathy, PKD = polycystic kidney disease, MI = myocardial infarction, PAD = peripheral arterial 
disease, ACR = albumin-to-creatinine ratio, eGFR = estimated glomerular filtration rate, LDL = low-density lipoprotein, HDL = high-density lipoprotein, hsCRP = high-sensitive 
C-reactive protein, PTH = parathyroid hormone, ARB = angiotensin receptor blocker, ACEi = angiotensin converting enzyme inhibitor, CCB = calcium channel blocker.
*Data are expressed as median and ranges (minimum to maximum).
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of eGFR, cholesterol, hemoglobin, and albumin than the other 
subcohorts (P < 0.001 for all). Of the entire cohort, 85.2% had 
been treated with an angiotensin receptor blocker (79.8%) or 
an angiotensin-converting enzyme inhibitor (11.1%) and 127 
(5.7%) patients had taken dual blockades.
 The baseline characteristics according to CKD stages are pre-
sented in Table 2. The prevalences of hypertension, diabetes, 
and macroalbuminuria were significantly higher in patients 
with advanced stages of CKD (P < 0.001 for all). These groups 
were older and included more female patients (P < 0.001, re-
spectively). In addition, the serum levels of cholesterol, hemo-
globin, and albumin were lower, whereas those of phosphorus, 
high-sensitive C-reactive protein (hsCRP), and intact parathy-
roid hormone were higher across the CKD stages (P = 0.001 for 
hsCRP, P < 0.001 for the others).
Cardiovascular risk profiles by 4 subcohorts
The prevalence of any CVD in the entire cohort was 14.4% (Ta-
ble 1). A total of 1.6% and 6.0% patients had prior history of MI 
and stroke, respectively. The overall prevalence of CVD was 
higher in the DN and HTN subcohorts than in the GN and PKD 
subcohorts. Approximately 5% of patients had coronary disease, 
and the prevalence was significantly higher in the DN subco-
hort (11.6%). The DN subcohort also had higher levels of SBP 
(P < 0.001 for each subcohort), and cardiac troponin T (P < 0.001 
for each subcohort) than the other subcohorts. To further delin-
eate cardiovascular risk, arterial stiffness, CAC score, and left 
ventricular geometry were evaluated. Compared with the other 
subcohorts, the DN subcohort had significantly higher baPWV 
(Fig. 1A) (1,803.8 ± 375.2 cm/s, P < 0.001 for each subcohort). 
When the CAC score was grouped into 4 categories based on 
the cutoff values of 0, 1–400, 401–1,000, and > 1,000, the preva-
lence of each group was as follows: 47.7% for the 0 group, 39.5% 
for the 1–400 group, 7.1% for the 401–1,000 group, and 5.7% for 
the > 1,000 group (Fig. 2A). The DN subcohort had significantly 
higher CAC scores (495.5 ± 826.9, P < 0.001 for each subcohort) 
and more patients with a CAC score of > 1,000 than the other 
subcohorts (15.8%). The mean LVMI was 88.5 ± 23.4 g/m2 in fe-
male patients and 97.3 ± 25.9 g/m2 in male patients (Fig. 3). The 
level of LVMI was significantly higher in the DN subcohort than 
in the GN and PKD subcohorts (103.0 ± 25.0 g/m2, P < 0.001 for 
each subcohort). In addition, both eccentric LVH and concen-
tric LVH were more predominant in the DN subcohort (eccen-
tric LVH, 16.4%; concentric LVH, 21.3%) than in the GN and PKD 
subcohorts (Fig. 4, P < 0.001 for each subcohort). All these adverse 
features were also observed in the HTN subcohort. The degree 
of cardiovascular risk profiles was less severe than that in the 
DN subcohort, but worse than those in the other 2 subcohorts.
Fig. 1. baPWV of the participants. (A) baPWV according to the etiology of CKD. (B) baPWV according to the CKD stages.
baPWV = brachial-ankle pulse wave velocity, CKD = chronic kidney disease, GN = glomerulonephritis, DN = diabetic nephropathy, HTN = hypertensive nephropathy, PKD = 
polycystic kidney disease.
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Fig. 2. Categories of CAC score in the participants. (A) CAC according to the etiology of CKD. (B) CAC according to CKD stages.
CAC = coronary arterial calcium, CKD = chronic kidney disease, GN = glomerulonephritis, DN = diabetic nephropathy, HTN = hypertensive nephropathy, PKD = polycystic kid-
ney disease.
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Cardiovascular risk profiles according to CKD stages
We also compared the cardiovascular risk profiles according to 
CKD stages. The prevalence of CVD increased as the CKD stage 
became more advanced (Table 2). In addition, SBP and the lev-
els of hsCRP and cardiac troponin T were significantly higher in 
patients with advanced stages of CKD. Furthermore, the baPWV, 
CAC score, and LVMI were also higher across the CKD stages. 
When the relation between eGFR and these parameters was as-
sessed by using the Spearman correlation coefficient, eGFR 
was found to be inversely correlated with hsCRP (r = −0.129, 
P < 0.001), cardiac troponin T (r = −0.637, P < 0.001), baPWV 
(r = −0.340, P < 0.001), CAC score (r = −0.245, P < 0.001), and 
LVMI (r = −0.272, P < 0.001) (Table 3). In subgroup analyses, 
baPWV (r = −0.111, P = 0.02), troponin T (r = −0.273, P < 0.001), 
hsCRP (r = −0.098, P = 0.030), and LVMI (r = −0.267, P < 0.001) 
was correlated with eGFR in DN subgroup, whereas LVMI (r =  
−0.187, P < 0.001) was only correlated with eGFR in HTN sub-
group. We also examined the relationship between these pa-
rameters and urinary ACR (Table 4). In all subjects, cardiovas-
cular parameters except hsCRP were significantly correlated 
Fig. 3. LVMI of the participants. (A) LVMI according to the etiology of CKD. (B) LVMI according to CKD stages.
LVMI = left ventricular mass index, CKD = chronic kidney disease, GN = glomerulonephritis, DN = diabetic nephropathy, HTN = hypertensive nephropathy, PKD = polycystic 
kidney disease.
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Fig. 4. LV geometry of the participants. (A) LV geometry according to the etiology of CKD. (B) LV geometry according to CKD stages.
LV = Left ventricular, CKD = chronic kidney disease, GN = glomerulonephritis, DN = diabetic nephropathy, HTN = hypertensive nephropathy, PKD = polycystic kidney disease.
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Table 3. Correlations of cardiovascular parameters with eGFR
Variables
Total DN HTN
r P value r P value r P value
baPWV −0.340 < 0.001 −0.111 0.020 −0.036 0.510
Troponin T −0.637 < 0.001 −0.273 < 0.001 −0.112 0.080
hsCRP −0.129 < 0.001 −0.098 0.030 −0.045 0.380
LVMI −0.272 < 0.001 −0.267 < 0.001 −0.187 < 0.001
CAC −0.245 < 0.001 −0.057 0.210 0.033 0.520
eGFR = estimated glomerular filtration rate, DN = diabetic nephropathy, HTN = hyper-
tensive nephropathy, baPWV = brachial-ankle pulse wave velocity, hsCRP = high-sen-
sitive C-reactive protein, LVMI = left ventricular mass index, CAC = coronary arterial 
calcium. 
Table 4. Correlation of cardiovascular parameters with urine ACR
Variables
Total DN non-DN
r P value r P value r P value
baPWV 0.285 < 0.001 0.119 0.133 0.167 < 0.001
Troponin T 0.212 < 0.001 0.262 0.001 0.114 0.004
hsCRP 0.019 0.564 0.052 0.511 0.021 0.581
LVMI 0.251 < 0.001 0.313 < 0.001 0.135 < 0.001
CAC 0.110 0.001 −0.041 0.588 0.080 0.029
ACR = albumin to creatinine ratio, DN = diabetic nephropathy, baPWV = brachial-an-
kle pulse wave velocity, hsCRP = high-sensitive C-reactive protein, LVMI = left ven-
tricular mass index, CAC = coronary arterial calcium.
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with albuminuria, and this association also found in non-DN 
subcohort. However, only troponin T (r = 0.262, P = 0.001) and 
LVMI (r = 0.313, P < 0.001) were significantly associated with 
ACR in DN subcohort.
DISCUSSION
In this study, we evaluated the baseline cardiovascular charac-
teristics in Korean adult patients with CKD. We found that the 
prevalence of CVD was 14.4%, and higher in the DN and HTN 
subcohorts. The DN subcohort exhibited worst cardiovascular 
risk profiles, followed by the HTN subcohort. In addition, the 
cardiovascular risk profiles became worse in advanced stages 
of CKD and all parameters representing cardiovascular risk were 
inversely correlated with eGFR. These findings suggest that CKD 
patients have a high cardiovascular risk, particularly in the pres-
ence of DN and severe kidney disease.
 It should be noted that the prevalence of CVD in our study 
was relatively lower than that reported in previous CKD cohorts 
from the United States and Japan (10,15). A direct comparison 
of CVD prevalence is not feasible because there are many dif-
ferences between the study cohorts. In particular, the KNOW-
CKD study had more patients with earlier stages of CKD than 
the other cohorts. Nevertheless, when we compared only pa-
tients with advanced stages of CKD (eGFR < 30 mL/min/1.73 
m2), the prevalence of CVD in our study (20.0%) was still lower 
than that in the United States (39.6%) and Japan (27.9%). Some 
demographic and clinical factors may explain these differences. 
The subjects in our cohort (53.7 years) were younger than those 
in the U.S. and Japanese cohorts (58.2 and 60.8 years, respec-
tively), and the prevalence of diabetes (33.7%) was lower than 
those in the 2 cohorts (48.0% and 37.6%, respectively). The blood 
pressure, BMI, lipid profiles, and hsCRP levels also differed among 
the cohorts—they were more favorably controlled in our cohort. 
Ethnicity may also have an influence on the different prevalenc-
es of CVD. Generally, it has been suggested that Asians have a 
lower cardiovascular burden than the other ethnic groups. In 
the United States, Asian Americans had lower ESRD mortality 
than white Americans (22). In line with this finding, the Dialysis 
Outcomes and Practice Patterns Study showed that the mortal-
ity rates in ESRD patients in the United States and Europe were 
significantly higher than those in Japan (23). This observational 
study also found that the prevalences of coronary disease and 
cerebrovascular disease were lower in Japanese patients. The 
practical patterns of dialysis vary across countries, which can 
also contribute to differences in cardiovascular burden. CVD is 
a consequence of complex interactions between genetic and 
environmental risk factors. Differences in regional socio-eco-
nomic status, dietary habits, and genetic factors may result in 
different cardiovascular risks. In this regard, it would be inter-
esting to see whether this relatively low cardiovascular burden 
in our cohort will lead to superior outcomes in the future, after 
these patients start dialysis therapy, compared with those seen 
in Western countries.
 Not surprisingly, the KNOW-CKD study showed that diabetic 
patients were at a high risk for CVD, as previously reported in 
other cohort studies (10,15,24). With the rapid transition to a 
Westernized lifestyle, the prevalence of diabetes has increased 
during the last decades in Korea, and about 10% of persons with-
out CKD aged ≥ 30 years had diabetes (25). A recent study us-
ing the Korean National Health and Nutrition Examination Sur-
vey V reported that the prevalence of CKD was 5 times higher in 
patients with diabetes than in those without, and that diabetic 
patients were more likely to have advanced stages of CKD (26). 
Accordingly, it is not surprising that diabetes has been a leading 
cause of ESRD, and that half of the ESRD patients started recei-
ving dialysis because of DN in Korea. In this study, all parame-
ters representing adverse cardiovascular risk were significantly 
higher in the DN subcohort. Because the cardiovascular risk 
profiles deteriorated in patients with advanced stages of CKD 
and were inversely correlated with eGFR, the lower eGFR in the 
DN subcohort may further aggravate the cardiovascular bur-
den. Therefore, it is very likely that these patients will develop 
adverse cardiovascular events in the future, although most of 
the patients did not have overt CVD at baseline.
 The baseline cardiovascular characteristics in the KNOW-
CKD cohort are similar to those of other cohorts in that cardio-
vascular risks were high in the advanced stages of CKD. In this 
study, we showed that the baPWV, LVMI, and CAC score were 
higher in the advanced stages of CKD and were inversely corre-
lated with eGFR. These findings are not novel, but are in agree-
ment with many other studies (27-29). All 3 parameters have 
been considered important determinants of adverse cardiovas-
cular outcomes in CKD patients (30-32). However, most studies 
have not conducted follow-up examinations, and their findings 
were based on cross-sectional analyses. Arterial stiffness, LVH, 
and vascular calcification are dynamic processes that inevitably 
progress as the kidney function declines. The KNOW-CKD study 
will observe the changes of these parameters by performing 
follow-up tests such as PWV, echocardiography, and CT scan, 
and will be able to provide novel insights with respect to struc-
tural and functional alterations of vasculature in CKD patients. 
In addition, our cohort study will perform follow-up on a vari-
ety of cardiovascular biomarkers such as hsCRP, cardiac tropo-
nin T, adiponectin, klotho, and fibroblast growth factor 23. More 
in-depth investigations will be performed to clarify the associa-
tions between these biomarkers and the future adverse cardio-
vascular outcomes, and to explore whether the biomarkers can 
play a role in the dynamic alterations of vasculature in CKD pa-
tients.
 Our study has several limitations. First, although the KNOW-
CKD is the first and largest CKD cohort study in Korea, its find-
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ings may not represent the entire population of CKD in Korea. 
The prevalence of CVD can significantly vary among etiologies 
of CKD, and different proportions of causative diseases can re-
sult in differences in cardiovascular risk. In fact, our cohort in-
cluded more patients with PKD than the other cohort studies. 
As seen in our study, the cardiovascular risk profiles in these 
patients were lower than those in the DN and HTN cohorts. How-
ever, a high prevalence of CVD in PKD patients was also report-
ed previously because hypertension, LVH, cardiac valvular ab-
normalities, and intracranial aneurysm can occur during the 
disease course (33). Therefore, it is reasonable to include a vari-
ety of kidney diseases in a CKD cohort study. Second, our ob-
servations were based on cross-sectional analyses and could 
not confirm causality. This is a common limitation of all cohort 
studies. However, cohort studies have many strengths, includ-
ing their ability to clarify the temporal sequence between expo-
sure and outcome, estimate the precise incidence of outcome 
and relative risk, and allow the examination of multiple compli-
cated effects of a specific causative factor. From the viewpoint 
of cardiovascular risk in CKD, we hope that this cohort study 
will be able to find some novel biomarkers and therapeutic tar-
gets, and also to provide guidelines for preventing adverse car-
diovascular events and mortality in patients with CKD.
 In conclusion, this study shows that the KNOW-CKD cohort 
exhibits a high cardiovascular burden, as other CKD cohorts in 
previous studies. Among the subcohorts, the DN subcohort posed 
the greatest risk for CVD. The ongoing long-term follow-up study 
up to 10 years will further delineate the cardiovascular charac-
teristics and outcomes of each subcohort with different risk pro-
files.
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